Newswire (Published: Wednesday, August 19, 2020, Received: Wednesday, August 19, 2020, 6:29:19 PM CDT)

Word Count: 488

2020 AUG 19 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting out of Rochester, Minnesota, by NewsRx editors, research stated, “The clinical course in metastatic castrate-resistant prostate cancer (mCRPC) can be complicated when patients have disease progression after prior treatment with second generation hormone therapy (second HT), such as enzalutamide or abiraterone. Currently, limited data exist regarding the optimal choice of chemotherapy for mCRPC after failing second generation hormone therapy.”

Our news journalists obtained a quote from the research from Mayo Clinic, “We sought to evaluate three common chemotherapy regimens in this setting. We retrospectively identified 150 mCRPC patients with disease progression on enzalutamide or abiraterone. Of these 150 patients, 92 patients were chemo-naive while 58 patients had previously received docetaxel chemotherapy before being started on second HT. After failing second HT, 90 patients were assigned for docetaxel-alone (group A), 33 patients received carboplatin plus docetaxel (group B), while 27 patients received cabazitaxel-alone (Group C). A favorable response was defined by more than or equal to 50% reduction in prostate-specific antigen from the baseline level after a complete course of chemotherapy. Survival outcomes were assessed for 30-month overall survival. Patients in group (B) were 2.6 times as likely to have a favorable response compared to patients in group (A) (OR = 2.625, 95%CI: 1.15-5.99) and almost three times compared to patients in group (C) (OR = 2.975, 95%CI: 1.04-8.54) (P = .0442). 30-month overall survival was 70.7%, 38.9% and 30.3% for group (B), (A), and (C), respectively (P = .008).”

According to the news editors, the research concluded: “We report a Hazard Ratio of 3.1 (95% CI, 1.31-7.35;P = .0037) between patients in group (A) versus those in group (B) and a Hazard Ratio of 4.18 (95% CI, 1.58-11.06;P = .0.”

For more information on this research see: Adding Carboplatin To Chemotherapy Regimens for Metastatic Castrate-resistant Prostate Cancer In Postsecond Generation Hormone Therapy Setting: Impact On Treatment Response and Survival Outcomes. The Prostate, 2020;():. The Prostate can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.

Our news journalists report that additional information may be obtained by contacting Mohamed E. Ahmed, Mayo Clinic, Dept. of Urology, 200 First St SW, Rochester, MN 55905, United States. Additional authors for this research include Jack R. Andrews, Jamal Alamiri, Julianna Higa, Rimki Haloi, Manaf Alom, Giovanni Motterle, Vidhu Joshi, Paras H. Shah, R. Jeffrey Karnes and Eugene Kwon.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/pros.24048. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Mayo Clinic

Places

North America
United States
Americas
Minnesota
Rochester

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
      Medical Specialties and Practices
            Urology
      Treatments and Therapies
            Chemotherapy